Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Abeona Therapeutics Inc shares valued at $132,740 were sold by Seshadri Vishwas on Dec 29 ’25. At $5.31 per share, Seshadri Vishwas sold 25,000 shares. The insider’s holdings dropped to 1,164,818 shares worth approximately $6.05 million following the completion of this transaction.
Also, Seshadri Vishwas purchased 25,000 shares, netting a total of over 132,695 in proceeds.
Before that, Alvino Mark had sold 15,000 shares from its account. In a trade valued at $71,168, the Director traded Abeona Therapeutics Inc shares for $4.74 each. Upon closing the transaction, the insider’s holdings decreased to 15,000 shares, worth approximately $0.32 million.
Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early March. As of July 03, 2024, H.C. Wainwright has initiated its “Buy” rating for ABEO. Earlier on May 30, 2024, Stifel initiated its rating. Their recommendation was “a Buy” for ABEO stock.
Analyzing ABEO Stock Performance
On last trading session, Abeona Therapeutics Inc [NASDAQ: ABEO] rose 1.96% to $5.19. The stock’s lowest price that day was $5.065, but it reached a high of $5.205 in the same session. During the last five days, there has been a drop of approximately -0.57%. Over the course of the year, Abeona Therapeutics Inc shares have dropped approximately -7.49%.
Is Abeona Therapeutics Inc subject to short interest?
Stocks of Abeona Therapeutics Inc saw a sharp steep in short interest on 2025-12-31 dropping by -0.57 million shares to 13.25 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 13.81 million shares. A decline of -4.27% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.33 of the overall float, the days-to-cover ratio (short ratio) decline to 11.33.
Which companies own the most shares of Abeona Therapeutics Inc (ABEO)?
In terms of Abeona Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 16 in the next 12 months, up nearly 214.34% from the previous closing price of $5.09. Analysts anticipate Abeona Therapeutics Inc stock to reach 20 by 2026, with the lowest price target being 6. In spite of this, 2 analysts ranked Abeona Therapeutics Inc stock as Buy at the end of 2026. On November 11, 2020, Cantor Fitzgerald assigned a price target of “an Overweight” to the stock and upgraded coverage with a $4.
